Cargando…
Comparison of Bacterial Risk in Cryo AHF and Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Until November 2020, cryoprecipitated antihaemophilic factor (cryo AHF) was the only United States Food and Drug Administration (FDA)-approved fibrinogen source to treat acquired bleeding. The post-thaw shelf life of cryo AHF is limited, in part, by infectious disease risk. Concerns over product was...
Autores principales: | Lu, Thea, Nahata, Pallavi, Johnson, Aja, Keltner, Nadia, Peters, Lindsay, McCormack, Melissa, Muñoz, Bianca, Krath, Mary, Weiner, Elan, Bringmann, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317717/ https://www.ncbi.nlm.nih.gov/pubmed/35889990 http://dx.doi.org/10.3390/pathogens11070744 |
Ejemplares similares
-
Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate
por: Collins, P. W., et al.
Publicado: (2014) -
Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate
por: Stanford, Sophia, et al.
Publicado: (2023) -
The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis
por: Whyte, Claire S., et al.
Publicado: (2022) -
Cryoprecipitate therapy
por: Nascimento, B., et al.
Publicado: (2014) -
Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric cardiac surgery (FICCS study)
por: Galas, F, et al.
Publicado: (2012)